Florin-George M.
- Country
- Romania
- Department
- Gastroenterology
Research Overview
- Long‑Term Safety and Efficacy of SPY001‑001 Monotherapy and Combination Therapy with Long‑Acting Antibodies in Adults with Ulcerative Colitis
- Phase II Randomized, Placebo-Controlled Study of Rifamycin SV Sodium In Situ Gelling Solution for Mild to Moderate Left-Sided Ulcerative Colitis
- Comparative Efficacy, Safety, and Immunogenicity of Intravenous AVT16 Versus Vedolizumab in Adults with Moderate to Severe Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 195 of 306 partner sites.
Specializations
Ulcerative colitis
Clinical research activity is centered on moderate to severe active ulcerative colitis, with additional interest in mild to moderate left-sided ulcerative colitis. The therapeutic focus includes induction and maintenance of clinical remission, as well as control of ongoing mucosal inflammation in patients managed through gastroenterology practice.
- Clinical remission
- Maintenance therapy
- Left-sided ulcerative colitis
Work in this area includes evaluation of targeted treatments and biologic options for patients with active disease requiring sustained symptom control.
Crohn’s disease
Research involvement extends to moderately to severely active Crohn’s disease, reflecting interest in therapies aimed at improving inflammatory bowel disease outcomes through both induction of response and longer-term disease control.
- Inflammatory bowel disease
- Induction of response
- Severe intestinal inflammation
The clinical focus supports investigation of treatment strategies for patients with persistent gastrointestinal inflammation and complex disease burden.
Biologic and biosimilar therapies
The investigator is involved in studies of biologic therapy and biosimilar treatment for inflammatory bowel disease, including comparative assessment of agents used in ulcerative colitis. This area reflects a therapeutic interest in expanding access to advanced targeted treatments.
- Biosimilar efficacy
- Targeted immunotherapy
- Comparative treatment evaluation
These activities align with the clinical use of innovative agents designed to modulate intestinal inflammation in patients with active disease.
Novel anti-inflammatory treatments
Another area of interest is the assessment of novel anti-inflammatory therapies for bowel disease, including locally delivered and long-acting approaches intended to improve control of colonic inflammation and support remission in patients with active ulcerative colitis.
- Rectal therapy
- Long-acting antibodies
- Histologic disease activity
This therapeutic domain includes strategies aimed at both symptomatic relief and deeper inflammatory control within specialized gastrointestinal care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.